Blood cell activation in myeloproliferative neoplasms

Haematologica

Volumn 94, Issue 11, 2009, Pages 1484-1488

  Cervantes, Francisco ^a   Arellano Rodrigo, Eduardo ^b   Alvarez Larrán, Alberto ^c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN; JANUS KINASE 2;

BASOPHIL; BLOOD CELL; BLOOD CLOTTING; CELL ACTIVATION; EDITORIAL; GENE MUTATION; HUMAN; LEUKOCYTE ACTIVATION; MAST CELL; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NONHUMAN; POLYCYTHEMIA VERA; THROMBOCYTE ACTIVATION; THROMBOCYTHEMIA; THROMBOSIS;

BLOOD CELLS; HUMANS; JANUS KINASE 2; LEUKOCYTES; MYELOPROLIFERATIVE DISORDERS; THROMBOPHILIA;

EID: 70449346183     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.013375     Document Type: Editorial

References (29)

1. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008;22:905-914 (Pubitemid 351698623)
2. De Stefano V, Za T, Rossi E, Fiorini A, Ciminello A, Luzzi C, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica 2009;94:733-737
3. Samuelsson J, Berg A. Further studies of the defective stimulus- response coupling for the oxidative burst in neutrophils in polycythemia vera. Eur J Haematol 1991;47:239-245
4. Westwood NB, Copson ER, Page LA, Mire-Sluis AR, Brown KA, Pearson TC. Activated phenotype in neutrophils and monocytes from patients with primary proliferative polycythaemia. J Clin Pathol 1995;48:525-530
5. Carulli G, Minnucci S, Azzara A, Gianfaldoni ML, Angiolini C, Sagripanti A, et al. Neutrophil functions in essential thrombocythemia. Hematol Pathol 1995;9:37-47.
6. Iki S, Yuo A, Yagisawa M, Inuo EK, Inoue Y, Usuki K, et al. Increased neutrophil respiratory burst in myeloproliferative disorders: selective enhancement of superoxide release triggered by receptor-mediated agonists and low responsiveness to in vitro cytokine stimulation. Exp Hematol 1997;25:26-33. (Pubitemid 27063740)
7. Wolach B, Gavrieli R, Manor Y, Lishner M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis 1998;24:544-551 (Pubitemid 29086937)
8. Falanga A, Marchetti M, Evangelista V, Vignoli A, Licini M, Balicco M, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
9. Burgaleta C, González N, César J. Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia. Acta Haematol 2002;108:23-28 (Pubitemid 34982054)
10. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-175 (Pubitemid 43304135)
11. Alvarez-Larrán A, García-Pagán JC, Abraldes JG, Arellano E, Reverter JC, Bosch J, et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004;124:329-335 (Pubitemid 38167983)
12. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732-2736
13. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-530 (Pubitemid 40592168)
14. Maugeri N, Giordano G, Petrilli MP, Fraticelli V, de Gaetano G, Cerletti C, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006;4:2593-2598 (Pubitemid 44741554)
15. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143-151
16. Robertson B, Urquhart C, Ford I, Townend J, Watson HG, Vickers MA, et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V617 F status, clonality, and antiphospholipid antibodies. J Thromb Haemost 2007;5:1679-1685 (Pubitemid 47091411)
17. Falanga A, Marchetti M, Vignoli A, Balducci D, Russo L, Guerini V, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007;35:702-711 (Pubitemid 46601748)
18. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Colomer D, Villamor N, Bellosillo B, et al. Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. Am J Hematol 2009;84:102-108
19. Trappenburg MC, van Schilfgaarde M, Marchetti M, Spronk HM, ten Cate H, Leyte A, et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia. Haematologica 2009;94:911-918
20. Marchetti M, Castoldi E, Spronk HM, van OR, Balducci D, Barbui T, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood 2008;112:4061-4068
21. Kornberg A, Rahimi-Levene N, Yona R, Mor A, Rachmilewitz EA. Enhanced generation of monocyte tissue factor and increased plasma prothrombin fragment 1+2 levels in patients with polycythemia vera: mechanism of activation of blood coagulation. Am J Hematol 1997;56:5-11. (Pubitemid 27398051)
22. + cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-3682
23. Alvarez-Larrán A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis. Ann Hematol 2008;87:269-276
24. Leibundgut EO, Horn MP, Brunold C, Pfanner-Meyer B, Marti D, Hirsiger H, et al. Hematopoietic and endothelial progenitor cell trafficking in patients with myeloproliferative diseases. Haematologica 2006;91:1465-1472 (Pubitemid 44736112)
25. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood 2009;113:5246-5249
26. Pieri L, Bogani C, Guglielmelli P, Zingariello M, Rana RA, Bartalucci N, et al. The JAK2V617F mutation induces constitutive activation and agonist hypersensitivity in basophils of polycythemia vera. Haematologica 2009;94:1537-2475
27. Wang J, Ishii T, Zhang W, Sozer S, Dai Y, Mascarenhas J, et al. Involvement of mast cells by the malignant process in patients with Philadelphia chromosome negative myeloproliferative neoplasms. Leukemia 23:1577-1586
28. Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood 2009;113:5942-5950
29. Kovanen PT. Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 2007;217:105-122 (Pubitemid 46718148)